Paratek’s Strategic Acquisition Signals New Growth Phase

Following its transition to private ownership, Paratek Pharmaceuticals has executed a significant strategic move by acquiring Optinose in May 2025. The deal, valued at up to $330 million, grants Paratek control over XHANCE®, a chronic rhinosinusitis treatment, positioning the biotechnology firm to access a potential patient population exceeding 10 million individuals.

This acquisition represents a fundamental strategic shift for the company. Rather than maintaining sole reliance on its flagship antibiotic NUZYRA®, Paratek is actively constructing a diversified therapeutic portfolio. The transaction’s financial backing showcases confidence from prominent biotechnology investors, with B-FLEXION Life Sciences, Novo Holdings, and Oaktree Capital Management providing the substantial funding required.

The company’s radical strategic transformation finds its roots in its 2023 privatization. When Gurnet Point Capital and... Read more...